Balancing costs and benefits in cancer therapy and prevention

Annals of Oncology

Volumn 19, Issue SUPPL. 7, 2008, Pages

  Szucs, T D ^a   Dedes, K J ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYCLOPHOSPHAMIDE; FLUOROURACIL; IRINOTECAN; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ACUTE NONLYMPHOCYTIC LEUKEMIA; ADJUVANT THERAPY; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER PREVENTION; CANCER THERAPY; COLONOSCOPY; COLORECTAL CANCER; CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION MAKING; DRUG DOSE COMPARISON; DRUG MEGADOSE; HAIRY CELL LEUKEMIA; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH INSURANCE; HODGKIN DISEASE; HUMAN; LIFE EXPECTANCY; MAMMOGRAPHY; OVARY CANCER; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION; ARTICLE; ECONOMICS; NEOPLASM;

COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; NEOPLASMS;

EID: 53449091282     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn475     Document Type: Conference Paper

References (37)

1. Radice D, Redaelli A. Breast cancer management: Quality-of-life and cost considerations. Pharmacoeconomics 2003; 21: 383-396.
2. Elixhauser A. (eds.). Health care cost-benefit and cost-effectiveness analysis (CBA/CEA). From 1979 to 1990. a bibliography. Medical Care 1993; 31 (Suppl): JS1-JS149.
3. Bloom BS. Medical management and managing medical care: The dilemma of evaluating new technology. Am Heart J 1990; 119: 754-760.
4. Banta HD. Health Care Technology and its Assessment. Oxford, UK: Oxford Medical Publications 1993.
5. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. Oxford, UK: Oxford University Press 1996.
6. Blumenschein K, Johannesson M. Economic evaluation in healthcare: A brief history and future directions. PharmacoEconomics 1996; 10: 114-122.
7. Udvarhelyi IS, Colditz G, Rai A. Cost-effectiveness and cost-benefit analyses in the medical literature: Are the methods being used correctly? Ann Intern Med 1992; 116: 238-244.
8. Davies L, Coyle D, Drummond M. Current status of eonomic appraisal of health technology in the European Community: Report of the network. Soc Sci Med 1994; 38: 1601-1607.
9. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996; 313: 275-283.
10. Kassirer JP. Incorporating patients' preferences into medical decisions [editorial]. N Engl J Med 1994; 330: 1895-1896.
11. Ministry of Health (Ontario). Ontario Guidelines for Economic Analysis of Pharmaceutical Products. Toronto, Canada: Ministry of Health 1994.
12. Department of Health and Association of the British Pharmaceutical Industry. Guidelines for the Economic Evaluation Pharmaceutical. London, UK: Department of Health 1994.
13. Coyle D, Increasing the impact of economic evaluations on health-care decision making. Discussion Paper 108, York 1993.
14. Chalmers-I, Haynes B. Reporting, updating, and correcting systematic reviews of the effects of health care. BMJ 1994; 309: 862-865.
15. Buxton MJ, Drummond MF, Hout BA et al. Modelling in economic evaluation. A first and last resort? Health Economics 1997; 6: 217-227.
16. Drummond MF, Stoddard GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford, UK: Oxford Medical Publications 1987.
17. Task Force on Principles for Economic Analysis of Health Care Principles. Economic analysis of health care technology. A report on principles. Ann Intern Med 1995; 123: 61-70.
18. Drummond MF, Jefferson TO. Guid elines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313: 275-283.
19. Kassirer JP, Angell M. The journal's policy on cost effectiveness analysis. N Engl J Med 1994; 331: 669-670.
20. Commonwealth Department of Health, Housing and Community Services. Guidelines for the pharmaceutical industry on the preparation of submissions to the pharmaceutical benefits advisory committee. Canberra: Australian Government Publishing Service 1992.
21. Canadian Coordinating Office of Health Technology Assessment (CCOHTA). Guidelines for the economic evaluation of pharmaceutical. Ottawa, Canada: CCOHTA 1994 www.ccohta.com.
22. Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. N Engl J Med 2008; 358: 661-663.
23. Hillner BE. Role of decision analysis in relation to clinical trials and a US perspective of the Battelle model. Pharmacoeconomics 1996; 9 (Suppl 2): 30-36-6 Review.
24. Basu A, Meltzer D. Implications of spillover effects within the family for medical cost-effectiveness analysis. J Health Econ 2005; 24: 751-773.
25. Kievit J, van de Velde CJH. Utility and cost of carcinoembryonic antigen monitoring in colon cancer follow-up evaluation. A Markov analysis. Cancer 1990; 65: 2580-2587.
26. Desch CE, Lasala MR, Smith TJ et al. The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients following a chemotherapy relapse. J Clin Oncol 1992; 10: 200-209.
27. Hillner BE, Smith TJ, Desche CE. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. J Am Med Assoc 1992; 267: 2055-2061.
28. Tappenden P, Jones R, Paisley S, Carroll C. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer 2007; 43: 2487-2494.
29. Welch HG, Larson EB. Cost-effectiveness of bone marrow transplantation in acute nonlyphocytic leukemia. N Engl J Med 1989; 321: 807-812.
30. Neeser K, Szucs T, Bulliard JL et al. Cost-effectiveness analysis of a quality-controlled mammography screening program from the Swiss statutory health-care perspective: Quantitative assessment of the most influential factors. Value Health 2007; 10: 42-53.
31. Dedes KJ, Szucs TD, Imesch P et al. Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: A model-based analysis of the HERA and FinHer trial. Ann Oncol 2007; 18: 1493-1499.
32. Venditti LN, Venditti CP, Berry GT et al. Newborn screening by tandem mass spectrometry for medium-chain acyl-CoA dehydrogenase deficiency: A cost-effectiveness analysis. Pediatrics 2003; 112: 1005-1015.
33. Hillner BE, Smith TJ. Efficacy and cost-effectiveness adjuvant chemotherapy in woman with node-negative breast cancer. N Engl J Med 1991; 324: 160-168.
34. Ozer H, Golomb HM, Zimmerman H et al. Cost-benefit analysis of interferon alpha 2b in treatment of hairy cell leukemia. J Natl Cancer Inst 1989; 81: 594-602.
35. Berger K, Szucs T. Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective. Eur J Cancer 1998; 34: 1894-1901.
36. Rees GJG. Cost-effectiveness in oncology. Lancet 1985; 2: 1405-1408.
37. Ness RM, Holmes AM, Klein R, Dittus R. Cost-utility of one-time colonoscopic screening for colorectal cancer at various ages. Am J Gastroenterol 2000; 95: 1800-1811.